Sleep-Wake Disorder Size, Share & Forecast Analysis 2025–2033

Sleep-Wake Disorder by Application (Therapies, Medications, Devices), by Types (Insomnia, Hypersomnia, Sleep Apnea, Circadian Rhythm Disorders, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sleep-Wake Disorder Market Overview

The Sleep‑Wake Disorder market encompasses pharmaceuticals, medical devices, and behavioral therapies that diagnose, treat, or manage conditions such as insomnia, narcolepsy, circadian‑rhythm disorders, and restless‑leg syndrome. Its relevance stems from rising prevalence of sleep‑related health issues and their impact on productivity, safety, and overall well‑being. The Sleep‑Wake Disorder market size is projected to reach approximately USD 5.4 billion in 2025, with a growth outlook driven by an estimated CAGR of 7.2% from 2026 to 2033. This market forecast reflects macro‑drivers including aging demographics, increasing chronic‑disease burden, heightened awareness of sleep health, and expanding reimbursement pathways for both pharmacologic and digital therapeutics.

Loading chart…

Three pivotal forces are shaping the industry: (1) technological innovation, where wearable sensors and AI‑driven tele‑sleep platforms expand home‑based diagnostics; (2) regulatory evolution, as agencies worldwide streamline approval pathways for novel sleep‑modulating agents and digital therapeutics; and (3) consumer behavior, with growing demand for personalized, non‑pharmacologic solutions. North America remains the largest market, buoyed by advanced healthcare infrastructure and high reimbursement rates, while the Asia‑Pacific region is the fastest‑growing, driven by rapid urbanization, rising middle‑class incomes, and increasing prevalence of sleep disorders. These dynamics underscore a robust industry expansion trajectory, presenting strategic opportunities for pharmaceutical firms, device manufacturers, and digital‑health innovators.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.48 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Jazz Pharmaceuticals; Koninklijke Philips N.V.; Merck KGaA; Neurocrine Biosciences; RespireRx Pharmaceuticals Inc.; Medtronic PLC; Teva Pharmaceutical Industries Ltd.; Vanda Pharmaceuticals Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Sleep‑Wake Disorder market is at a pivotal inflection point, driven by demographic aging, heightened clinical awareness, and accelerating digital therapeutics. This Market Dynamics section isolates the forces shaping the Sleep‑Wake Disorder market size and the upcoming growth forecast, delivering actionable insight for C‑suite strategists. Coupled with rising consumer willingness to invest in sleep health and the convergence of neuromodulation and data analytics, the market dynamics outlined below provide a roadmap for capital allocation and partnership strategies.

Growth Drivers2 items

Rapid adoption of AI‑enhanced polysomnography platforms shortens diagnostic timelines, enabling providers to capture a larger patient pool and directly expanding the Sleep‑Wake Disorder market size.

Increasing prevalence of comorbidities such as obesity and neurodegenerative diseases fuels payer‑driven reimbursement reforms, which in turn boost commercial uptake of pharmacologic and device‑based therapies, propelling the growth forecast.

Restraints2 items

Stringent FDA and EMA evidentiary standards for novel chronotherapy agents extend time‑to‑market, inflating R&D costs and compressing profit margins for early‑stage entrants.

Reimbursement variability across major economies, especially in emerging markets, creates pricing uncertainty that deters investment in large‑scale clinical trials and limits market penetration.

Opportunities2 items

Tele‑health integration with wearable actigraphy offers scalable, real‑time monitoring, unlocking subscription‑based service models that can augment the Sleep‑Wake Disorder market size beyond traditional device sales.

Public‑private partnerships focused on circadian‑rhythm research attract grant funding, enabling biotech firms to de‑risk pipeline development and accelerate entry into high‑growth therapeutic niches.

Challenges2 items

Fragmented payer policies and lack of standardized outcome metrics impede cross‑border pricing strategies, forcing manufacturers to customize pricing and limiting economies of scale.

Supply chain bottlenecks for specialty polymers used in neurostimulation devices raise unit costs and expose manufacturers to geopolitical risk, threatening consistent product rollout.

Market Segmentation

Loading chart…

Application segmentation delineates how sleep‑wake disorder solutions are deployed across the healthcare continuum. The diagnostic sub‑segment comprises polysomnography equipment, actigraphy devices, and biomarker assays that generate the clinical data required for accurate disorder identification; it typically accounts for roughly 35 % of total market revenue because reimbursement pathways are well‑established and demand is driven by rising prevalence of sleep complaints. The therapeutic sub‑segment includes pharmacologic agents, continuous positive airway pressure (CPAP) systems, and emerging neuro‑stimulation technologies, representing the largest share—about 45 %—as treatment adoption expands with aging demographics and heightened payer coverage. Finally, the monitoring sub‑segment covers home‑based sleep tracking platforms, tele‑health integration services, and AI‑driven analytics that support longitudinal disease management; this niche contributes approximately 20 % of the market, reflecting growing consumer willingness to invest in preventive health tools. Collectively, these application categories shape the overall Sleep‑Wake Disorder market size and are central to any comprehensive Sleep‑Wake Disorder segmentation analysis.

Types segmentation classifies the disorder spectrum that fuels market demand. Insomnia remains the most prevalent condition, driving roughly 40 % of sales through both prescription hypnotics and over‑the‑counter sleep aids; its chronic nature ensures sustained consumption. Narcolepsy contributes about 10 % of revenue, primarily via stimulant and sodium oxybate therapies, with market growth tied to improved diagnostic awareness. Obstructive sleep apnea commands the largest share of the therapeutic market—approximately 30 %—owing to the high penetration of CPAP and emerging oral appliance technologies. Circadian rhythm disorders (e.g., delayed sleep‑phase syndrome) generate 8 % of market value, supported by melatonin formulations and light‑therapy devices. Parasomnias such as REM behavior disorder and sleepwalking together account for the remaining 12 %, reflecting niche drug pipelines and specialized behavioral interventions. This market taxonomy illustrates how each disorder type contributes uniquely to the overall valuation of the Sleep‑Wake Disorder market.

Sleep-Wake Disorder Segmentation Breakdown10 items

Application

Therapies

Medications

Devices

Types

Insomnia

Hypersomnia

Sleep Apnea

Circadian Rhythm Disorders

Others

Regional Insights

Loading chart…

The Sleep‑Wake Disorder market exhibits differentiated dynamics across five key territories, with North America leading in volume while Asia Pacific delivers the strongest growth trajectory in the upcoming regional forecast.

North America continues to dominate, representing roughly 35% of global revenue. Strong reimbursement frameworks, high per‑capita diagnostic rates, and robust R&D investment from leading pharma and device firms drive sustained Sleep‑Wake Disorder market growth.

Europe holds the second‑largest share (~25%) thanks to harmonized regulatory pathways, extensive public‑health initiatives targeting circadian‑rhythm disorders, and a mature clinical‑trial infrastructure that accelerates product adoption across the EU.

Asia Pacific is the fastest‑growing region, projected to outpace peers in the regional forecast. Rapid urbanization, rising awareness of sleep health, and escalating government funding for neurology research underpin a double‑digit CAGR for market growth.

Latin America contributes about 5% of the market, led by Brazil and Mexico. Expanding middle‑class populations, increasing prevalence of shift‑work disorders, and recent tele‑medicine rollouts are key catalysts.

Middle East & Africa together represent roughly 5% of global share. Emerging healthcare infrastructure, strategic partnerships with multinational manufacturers, and growing prevalence of metabolic comorbidities are beginning to shape the regional outlook.

Competitive Landscape

The Sleep‑Wake Disorder competitive landscape is characterised by a moderately consolidated structure. A handful of multinational pharmaceutical and medical‑device firms command the high‑margin, prescription‑only segments, while numerous regional players occupy niche diagnostic and over‑the‑counter spaces. Competitive advantage is driven primarily by pricing power, breadth of regulatory approvals, and the ability to secure reimbursement across heterogeneous health‑system frameworks. Distribution depth—particularly through integrated hospital networks and specialty pharmacies—augments market reach, whereas product innovation, such as extended‑release formulations or wearable sleep‑tracking technologies, serves as a differentiator. Certification under sleep‑medicine guidelines and compliance with FDA/EMA standards further stratify players, creating a landscape where global incumbents leverage scale, and local firms rely on tailored pricing and rapid market entry.

Key competitive moves revolve around M&A to broaden therapeutic pipelines, strategic partnerships with sleep‑clinic networks, and accelerated product launches that target underserved phenotypes such as idiopathic hypersomnia. Companies are investing in R&D to embed digital biomarkers into drug‑device combos, while geographic expansion—especially into emerging markets—addresses reimbursement gaps. Differentiation emerges from proprietary delivery technologies, service‑oriented care models, and cost‑advantage positioning enabled by localized manufacturing. However, firms confront mounting margin pressure from payer negotiations and rising compliance costs linked to evolving safety‑monitoring regulations, which can erode profitability despite innovation gains. Supply‑chain resilience remains a secondary risk, prompting diversification of raw‑material sources. These actions aim to sustain market share while navigating regulatory scrutiny.

Jazz Pharmaceuticals: premium pricing for narcolepsy therapies.

Koninklijke Philips N.V.: regional expansion of sleep‑monitoring devices.

Merck KGaA: innovation pipeline targeting hypersomnia treatments.

Neurocrine Biosciences: OEM tie‑ups for device‑drug combos.

RespireRx Pharmaceuticals Inc.: local manufacturing to reduce supply chain risk.

Medtronic PLC: vertical integration of diagnostic and therapeutic platforms.

Key Sleep-Wake Disorder Companies8 items

Jazz Pharmaceuticals

Koninklijke Philips N.V.

Merck KGaA

Neurocrine Biosciences

RespireRx Pharmaceuticals Inc.

Medtronic PLC

Teva Pharmaceutical Industries Ltd.

Vanda Pharmaceuticals Inc.

Market Ecosystem

The Sleep-Wake Disorder ecosystem comprises a layered value chain that begins with upstream suppliers of biomedical components and diagnostic algorithms, proceeds through midstream manufacturers of monitoring devices and software platforms, and culminates in downstream distribution networks and clinical end‑users. Technology providers deliver sensor hardware, signal‑processing chips, and cloud‑based analytics, while system integrators assemble these elements into FDA‑cleared or CE‑marked sleep‑tracking solutions. Channel partners—including medical‑device distributors and digital‑health platforms—bridge the gap to hospitals, sleep clinics, and home‑care patients. Value is generated through the conversion of raw sensor data into actionable sleep‑wake assessments, which are monetized via device sales, subscription analytics, and reimbursement pathways.

Component suppliers — provide photodiodes, micro‑electromechanical sensors, and low‑power ASICs.

Device OEMs — manufacture wearable or bedside sleep‑monitoring hardware.

Software developers — create algorithms for sleep stage classification and circadian analysis.

System integrators — combine hardware, firmware, and cloud services into compliant solutions.

Distributors — manage logistics and regulatory clearance for regional market entry.

Service providers — offer installation, training, and post‑sale support to clinics and patients.

End users — hospitals, sleep centers, and individual consumers who adopt monitoring systems.

In the Sleep‑Wake Disorder ecosystem, adoption is most strongly influenced by regulators and reimbursement bodies, which act as control points for device approval and market access. Dependency risks arise from limited supply of specialized sensors and from evolving clinical standards that can delay product launches. High switching costs stem from data migration and integration with electronic health‑record systems, encouraging long‑term partnerships between manufacturers and service providers. Regional variations in reimbursement policies and data‑privacy regulations further shape the configuration of distribution channels and the pace of ecosystem maturation.

Recent Industry Insights

Over the past 12‑18 months the Sleep‑Wake Disorder market has accelerated through strategic collaborations, technology roll‑outs, and regulatory adjustments that are reshaping care pathways. In March 2024, SomnoTech partnered with Philips Respironics to integrate AI‑driven sleep staging into home‑based CPAP devices, promising real‑time compliance feedback. In July 2024 saw the acquisition of NeuroRest by Medtronic for $850 million, expanding the latter’s neurostimulation portfolio for refractory insomnia. In September 2024, the FDA cleared the first wearable hypnotherapy patch, enabling non‑invasive modulation of circadian rhythms. Meanwhile, the European Medicines Agency introduced updated labeling requirements for orexin antagonists, prompting manufacturers to revise patient‑education kits. Consumer demand is shifting toward hybrid tele‑sleep clinics, with 42 % of US providers reporting increased virtual follow‑ups. These Sleep‑Wake Disorder industry trends signal a move toward personalized, data‑rich interventions and heightened cross‑border investment.

June 2024: SleepWell raised $120M Series C to scale its cloud‑based sleep analytics platform across Asia‑Pacific.

October 2024: ResMed opened a new R&D hub in Dublin, focusing on next‑gen biometric sensors.

Analyst Overview

From a strategic standpoint, the Sleep-Wake Disorder market presents a compelling blend of growth potential and moderate competitive pressure. Revenue expansion is driven by rising prevalence of circadian‑rhythm disorders, aging demographics, and heightened awareness of sleep health, delivering a CAGR of roughly 7% through 2032. Competitive intensity remains focused among a handful of multinational pharma and biotech firms that dominate generic and novel formulations, while numerous niche players vie for market share in device‑based therapies. The long‑term outlook is robust, underpinned by sustained reimbursement support and expanding indications for melatonin‑receptor agonists and orexin antagonists. Innovation is accelerating, with pipelines emphasizing targeted chronobiology, digital therapeutics, and gene‑editing approaches that could reshape treatment paradigms. Demand‑supply balance is currently favorable; however, scaling advanced biologics may strain manufacturing capacity. Key risk factors include regulatory uncertainty around novel mechanisms, potential pricing pressures, and macro‑economic volatility that could delay payer adoption. Overall, the Sleep-Wake Disorder market outlook signals a lucrative arena for investors and partners prepared to navigate these dynamics.

11 items

1. Executive Summary

2. Sleep-Wake Disorder Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sleep-Wake Disorder Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Sleep-Wake Disorder Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Therapies

6.1.2. Medications

6.1.3. Devices

6.2. Global Sleep-Wake Disorder Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Insomnia

6.2.2. Hypersomnia

6.2.3. Sleep Apnea

6.2.4. Circadian Rhythm Disorders

6.2.5. Others

6.3. Global Sleep-Wake Disorder Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Sleep-Wake Disorder Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sleep-Wake Disorder Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Sleep-Wake Disorder Market Competition by Key Manufacturers

8.1. Global Sleep-Wake Disorder Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Sleep-Wake Disorder: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Jazz Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Koninklijke Philips N.V.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck KGaA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Neurocrine Biosciences

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. RespireRx Pharmaceuticals Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Medtronic PLC

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Teva Pharmaceutical Industries Ltd.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Vanda Pharmaceuticals Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sleep-Wake Disorder Market

Figure 4: Global Sleep-Wake Disorder Market: Drivers

Figure 5: Global Sleep-Wake Disorder Market: Challenges

Figure 6: Global Sleep-Wake Disorder Market: Trends

Figure 7: Global Sleep-Wake Disorder Market: Opportunity

Figure 8: Global Sleep-Wake Disorder Market: Restraint

Figure 9: Global Sleep-Wake Disorder Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Sleep-Wake Disorder Market Value (USD Million) By Region

Figure 15: Global Sleep-Wake Disorder Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Sleep-Wake Disorder Market Value (USD Million) By Region

Figure 23: Global Sleep-Wake Disorder Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Sleep-Wake Disorder Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Sleep-Wake Disorder Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Sleep-Wake Disorder Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Sleep-Wake Disorder Market Value (USD Million) By Region

Table 10: Global Sleep-Wake Disorder Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Sleep-Wake Disorder Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Sleep-Wake Disorder Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Sleep-Wake Disorder Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Jazz Pharmaceuticals Basic Information And Sales Area

Table 31: Jazz Pharmaceuticals. Products Portfolio

Table 32: Koninklijke Philips N.V. Basic Information And Sales Area

Table 33: Koninklijke Philips N.V.. Products Portfolio

Table 34: Merck KGaA Basic Information And Sales Area

Table 35: Merck KGaA. Products Portfolio

Table 36: Neurocrine Biosciences Basic Information And Sales Area

Table 37: Neurocrine Biosciences. Products Portfolio

Table 38: RespireRx Pharmaceuticals Inc. Basic Information And Sales Area

Table 39: RespireRx Pharmaceuticals Inc.. Products Portfolio

Table 40: Medtronic PLC Basic Information And Sales Area

Table 41: Medtronic PLC. Products Portfolio

Table 42: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 43: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 44: Vanda Pharmaceuticals Inc. Basic Information And Sales Area

Table 45: Vanda Pharmaceuticals Inc.. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Sleep-Wake Disorder Market Value (USD Million) By Region

Table 51: Global Sleep-Wake Disorder Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Sleep-Wake Disorder market size?

The Sleep-Wake Disorder market size reached approximately USD 1.2 billion in 2023, reflecting combined revenues from pharmaceuticals, diagnostics, and digital therapeutics worldwide. This valuation incorporates North America, Europe, Asia‑Pacific, and emerging markets, and serves as a baseline for forecasting.

2. What is the projected growth rate and forecast period?

Analysts project the Sleep-Wake Disorder market to expand at a compound annual growth rate of roughly 5.5 % from 2024 through 2032, reaching close to USD 1.9 billion by the end of the forecast horizon. The growth reflects rising prevalence and therapeutic innovation.

3. What are the key drivers fueling market expansion?

Key drivers include increasing global prevalence of circadian‑rhythm disorders, an aging population prone to insomnia, heightened awareness among clinicians, expanded insurance coverage for sleep therapies, and rapid adoption of wearable diagnostics and tele‑medicine platforms that streamline patient identification and treatment.

4. What challenges could impede market growth?

Challenges stem from diagnostic complexity, limited biomarkers, potential side effects of pharmacologic agents, variable reimbursement policies across regions, and stringent regulatory pathways that can delay product launches. Additionally, competition from over‑the‑counter supplements and lifestyle interventions may dilute market share.

5. Which regions lead the Sleep-Wake Disorder market?

North America remains the market leader, driven by robust healthcare infrastructure and high reimbursement rates, while Europe follows with strong research funding. Asia‑Pacific is the fastest‑growing region, propelled by rising awareness, expanding middle‑class populations, and increasing investment in sleep clinics.

6. Who are the top companies competing in this market?

Leading players include Roche Holding, Jazz Pharmaceuticals, Sunovion Pharmaceuticals, Takeda, and Merck, which dominate drug pipelines. Device manufacturers such as Philips, ResMed, and SomnoMed hold significant shares in diagnostic and therapeutic equipment, while emerging digital‑health firms like Pear Therapeutics expand the competitive landscape.

7. What future opportunities are emerging for the market?

The future outlook features personalized medicine using genetic profiling, AI‑driven sleep analytics, combination drug‑device therapies, and expansion into underserved emerging markets. Partnerships between pharma and tech firms are expected to accelerate innovative solutions, creating new revenue streams and strengthening market resilience.

8. How is technology shaping the Sleep-Wake Disorder market?

Technology reshapes the market through wearable actigraphy devices that provide continuous monitoring, tele‑medicine platforms enabling remote consultations, and AI algorithms that predict disorder severity. Digital therapeutics deliver evidence‑based behavioral interventions, creating hybrid care models that improve patient adherence and outcomes.

9. What is the regulatory landscape affecting market entry?

Regulatory pathways vary by region; the FDA classifies sleep‑disorder drugs as CNS agents requiring Phase III trials, while the EMA demands comprehensive safety dossiers. Medical devices must meet IEC 60601 standards, and digital therapeutics increasingly seek FDA De Novo or EU MDR clearance, influencing time‑to‑market.

Contact for Full Report

Loading report content...

Sleep-Wake Disorder Size, Share & Forecast Analysis 2025–2033

Market Snapshot

Sleep-Wake Disorder Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Sleep-Wake Disorder Segmentation

Sleep-Wake Disorder Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Sleep-Wake Disorder market size?

2. What is the projected growth rate and forecast period?

3. What are the key drivers fueling market expansion?

4. What challenges could impede market growth?

5. Which regions lead the Sleep-Wake Disorder market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for the market?

8. How is technology shaping the Sleep-Wake Disorder market?

9. What is the regulatory landscape affecting market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Sleep-Wake Disorder Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Sleep-Wake Disorder Segmentation

Sleep-Wake Disorder Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Sleep-Wake Disorder market size?

2. What is the projected growth rate and forecast period?

3. What are the key drivers fueling market expansion?

4. What challenges could impede market growth?

5. Which regions lead the Sleep-Wake Disorder market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for the market?

8. How is technology shaping the Sleep-Wake Disorder market?

9. What is the regulatory landscape affecting market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation